Vermiscab-A 6mg/400mg Tablet

Vermiscab-A 6mg/400mg Tablet is a broad-spectrum anthelmintic and antiparasitic medication that combines two distinct mechanisms of action to combat parasitic infestations. It is utilised to manage complex infections of the blood, intestines, and skin.

Albendazole, a benzimidazole derivative, works by interfering with the polymerisation of tubulin in the parasite. This disrupts the worm's cytoplasmic microtubules, leading to a failure in glucose uptake and the depletion of glycogen stores. Without an energy source, the parasite eventually dies. Ivermectin, an avermectin derivative, targets the glutamate-gated chloride channels in the nerve and muscle cells of invertebrates. By increasing the flow of chloride ions, it causes hyperpolarisation and immediate paralysis of the parasite, allowing the body's natural processes to clear the infection.

This combination is significant in the treatment of lymphatic filariasis (elephantiasis). It acts as a "gold standard" therapy by effectively killing the young, immature worms (microfilariae) circulating in the bloodstream, thereby preventing the spread of the disease. Furthermore, the addition of Ivermectin significantly enhances the efficacy of treatment against certain stubborn intestinal parasites, such as whipworms (Trichuriasis), which often show resistance to Albendazole alone.

By acting on different physiological pathways of the parasite, Vermiscab-A 6mg/400mg Tablet ensures a more comprehensive clearance of mixed infections. It is designed to be highly effective against the parasites while maintaining a high safety margin for the patient, as the specific targets of these medications are either absent or less accessible in the human nervous system.

Vermiscab-A 6mg/400mg Tablet may be indicated by your doctor for:

Lymphatic Filariasis (Elephantiasis)

To kill circulating microfilariae and help eliminate the Wuchereria bancrofti parasite.

Soil-Transmitted Helminths (STH)

Treatment of heavy or mixed intestinal worm loads, including giant roundworms (Ascariasis).

Trichuriasis (Whipworm)

Highly effective management of whipworm infections that are resistant to single-agent therapy.

Hookworm Infections

Treatment of intestinal parasites such as Ancylostoma duodenale or Necator americanus.

Strongyloidiasis

For persistent "threadworm" infections that require a multi-drug approach.

Severe or Crusted Scabies

Oral treatment for "Norwegian" scabies or difficult-to-treat skin infestations.

Cutaneous Larva Migrans

Management of "creeping eruption" caused by migrating animal hookworm larvae under the skin.

Vermiscab-A 6mg/400mg Tablet may provide benefits such as:

• Synergistic action that provides a higher cure rate for mixed parasitic infections than either drug used alone.

• Broad-spectrum coverage against a wide variety of roundworms, hookworms, and external mites.

• Effective management of resistant strains, particularly in the case of whipworm infections.

• Prevention of disease transmission by rapidly reducing the number of immature parasites in the bloodstream.

• Simplified dosing for mass drug administration programmes, often requiring only a single supervised dose.

• Dual-pathway targeting, which reduces the likelihood of parasites developing resistance to the treatment.

Vermiscab-A 6mg/400mg Tablet is generally well-tolerated, though side effects can occur as the body reacts to the clearing of the parasites.

Common side effects of Vermiscab-A 6mg/400mg Tablet may include

• Nausea or vomiting

• Dizziness or headache

• Abdominal pain or bloating

• Diarrhoea

• Tiredness

Uncommon side effects of Vermiscab-A 6mg/400mg Tablet may include

• Temporary thinning of hair (alopecia)

• Fever or shivering

• Itching or skin rash

• Elevation of liver enzymes (usually temporary)

Serious side effects that may require immediate medical attention include

• Mazzotti Reaction: A severe inflammatory response (fever, rapid heart rate, joint pain) caused by the death of many parasites at once.

• Signs of liver dysfunction (yellowing of eyes/skin, dark urine).

• Severe allergic reactions (swelling of the face, difficulty breathing).

• Significant vision changes or eye irritation.

• Severe skin peeling or blistering.

Always consult your doctor if you notice any unusual symptoms while taking Vermiscab-A 6mg/400mg Tablet.

Use Vermiscab-A 6mg/400mg Tablet exactly as directed by your doctor.

• Dosing: It is often prescribed as a single dose. Some severe infections may require a repeat dose after a few weeks.

• Oral Tablets: The tablets may be crushed or chewed and taken with water.

• Timing: For most intestinal parasites, it is often recommended to take the medication on an empty stomach. However, follow your doctor's specific advice as some infections may require taking it with a fatty meal to enhance absorption.

• Suspension: If using the liquid form, shake the bottle well and use a calibrated measuring cup.

• Hygiene: Maintain strict personal hygiene (hand washing, short nails) to prevent re-infection during and after treatment.

Vermiscab-A 6mg/400mg Tablet works by attacking parasites in two different ways.

The Albendazole component stops the parasite from absorbing sugar (glucose), which is its primary energy source. This leads to the "starvation" and eventual death of the worm. Simultaneously, the Ivermectin component binds to the parasite's nerve and muscle cells, causing chloride ions to flood in. This results in the immediate paralysis of the parasite. By combining these two actions, the medication ensures that the parasites are both weakened and unable to move, making it much easier for the body's immune and digestive systems to eliminate them.

• If you are being treated for a family-wide infestation (like pinworms or scabies), all household members should be treated at the same time.

• For intestinal worms, your doctor may suggest a repeat dose in 2 weeks to kill any worms that hatched from eggs after the first treatment.

• If you experience a mild fever or rash a day after treatment, it is often a sign that the medication is working and the parasites are dying.

• Avoid taking this medication if you have a history of seizures or neurological disorders without consulting a specialist.

• Ensure you drink plenty of fluids to stay hydrated if you experience diarrhoea as a side effect.

Store Vermiscab-A 6mg/400mg Tablet at room temperature in a dry place away from direct sunlight and moisture.

• Keep tablets in their original packaging until use.

• Keep the bottle of suspension tightly closed.

• Store safely out of the reach of children and pets.

• Do not use after the expiry date printed on the pack.

• Food (MODERATE): Food, especially fatty meals, may significantly increase the absorption of Vermiscab-A 6mg/400mg Tablet. This may improve effectiveness but can also increase exposure. Take as directed by your doctor.

• Grapefruit Juice (CAUTION): Grapefruit juice may increase drug levels by affecting metabolism. Clinical impact is not fully established. Avoid or limit use unless advised.

• Other Antiparasitic Agents (CONSULT YOUR DOCTOR): Concomitant use with additional antiparasitic drugs may increase gastrointestinal or hepatic side effects. Medical supervision is required to adjust therapy.

• Hepatotoxic Medications (CAUTION): Both Albendazole and Ivermectin undergo hepatic metabolism. Combining with drugs that affect liver function (e.g., certain antifungals, antibiotics, or anti‑TB agents) may elevate liver enzymes. Monitor liver function if co‑administered.

• Central Nervous System Depressants (MILD): Ivermectin may cause dizziness or drowsiness. Concurrent use with alcohol or sedating agents can enhance these effects.

• Liver Disease (MODERATE): Vermiscab-A 6mg/400mg Tablet is metabolised in the liver. Liver impairment may increase drug levels and risk of adverse effects. Monitoring of liver function is recommended.

• Neurocysticercosis / Seizure Risk (SEVERE): Treatment may cause inflammation in the brain as parasites are killed. This can lead to seizures or increased intracranial pressure. Use under close medical supervision.

• Bone Marrow Suppression (SEVERE): Use may reduce white blood cell counts. Rare cases of serious blood disorders have been reported. Blood count monitoring may be required during prolonged therapy.

An overdose may cause severe dizziness, vomiting, and loss of coordination. If an overdose is suspected, seek emergency medical help or contact a poison control centre immediately.

If you miss the scheduled dose, take it as soon as you remember. If it has been more than 24 hours since the missed dose, consult your doctor for instructions. Do not take a double dose.